SG10201505595WA - Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy - Google Patents

Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy

Info

Publication number
SG10201505595WA
SG10201505595WA SG10201505595WA SG10201505595WA SG10201505595WA SG 10201505595W A SG10201505595W A SG 10201505595WA SG 10201505595W A SG10201505595W A SG 10201505595WA SG 10201505595W A SG10201505595W A SG 10201505595WA SG 10201505595W A SG10201505595W A SG 10201505595WA
Authority
SG
Singapore
Prior art keywords
responding
patient
identify
cancer therapy
increased likelihood
Prior art date
Application number
SG10201505595WA
Inventor
Herbert Andres
Haas Sanne Lysbet De
Rebecca Elliott
Johann Karl
Yu-Ju Gloria Meng
Gregory D Plowman
Stefan Scherer
Norbert Wild
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG10201505595WA publication Critical patent/SG10201505595WA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
SG10201505595WA 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy SG10201505595WA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10170004 2010-07-19
EP10170008 2010-07-19
US41485310P 2010-11-17 2010-11-17
US201161497753P 2011-06-16 2011-06-16

Publications (1)

Publication Number Publication Date
SG10201505595WA true SG10201505595WA (en) 2015-09-29

Family

ID=45496541

Family Applications (8)

Application Number Title Priority Date Filing Date
SG10201505601RA SG10201505601RA (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG10201505593VA SG10201505593VA (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG10201505595WA SG10201505595WA (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG2013003868A SG187119A1 (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG2013002035A SG187018A1 (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG2013003892A SG187121A1 (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG2013003884A SG187120A1 (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG10201505414XA SG10201505414XA (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201505601RA SG10201505601RA (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG10201505593VA SG10201505593VA (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy

Family Applications After (5)

Application Number Title Priority Date Filing Date
SG2013003868A SG187119A1 (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG2013002035A SG187018A1 (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG2013003892A SG187121A1 (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG2013003884A SG187120A1 (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG10201505414XA SG10201505414XA (en) 2010-07-19 2011-07-18 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy

Country Status (14)

Country Link
US (12) US20130344059A1 (en)
EP (8) EP2596361A1 (en)
JP (8) JP2013534305A (en)
KR (5) KR20130126588A (en)
CN (8) CN103180738A (en)
AU (4) AU2011281701A1 (en)
BR (3) BR112013001433A2 (en)
CA (4) CA2805709A1 (en)
HK (1) HK1216039A1 (en)
MX (4) MX2013000674A (en)
RU (4) RU2013104302A (en)
SG (8) SG10201505601RA (en)
WO (4) WO2012010547A1 (en)
ZA (3) ZA201300305B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2012348600A1 (en) * 2011-12-05 2014-05-22 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
US9116159B2 (en) 2012-05-22 2015-08-25 Regeneron Pharmaceuticals, Inc. VEGF-A121 assay
KR20150024342A (en) * 2012-06-26 2015-03-06 에프. 호프만-라 로슈 아게 Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
US9953417B2 (en) * 2013-10-04 2018-04-24 The University Of Manchester Biomarker method
LT3524595T (en) 2014-08-28 2022-09-26 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
MX2017003387A (en) * 2014-09-16 2018-01-30 Regeneron Pharma Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer.
WO2016065626A1 (en) * 2014-10-31 2016-05-06 深圳市大疆创新科技有限公司 Gas leakage processing method and apparatus, and air vehicle
EP3218401B1 (en) * 2014-11-14 2020-03-04 F. Hoffmann-La Roche AG Predicting response to a vegf antagonist
RS65049B1 (en) 2015-02-25 2024-02-29 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
NZ735803A (en) * 2015-04-02 2021-12-24 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
WO2016204193A1 (en) 2015-06-16 2016-12-22 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ Anticancer agent
AU2017211247B2 (en) * 2016-01-25 2023-03-09 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
CN109477843A (en) * 2016-07-15 2019-03-15 豪夫迈·罗氏有限公司 For detecting the horizontal ways and means of total VEGF-A
RU2639253C1 (en) * 2016-12-30 2017-12-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Method for prediction of efficiency of prolonged radiation therapy for rectal cancer
CN108753984B (en) * 2018-08-28 2021-07-13 北京市神经外科研究所 Biomarker combination for predicting or diagnosing postoperative recurrence of brain malignant glioma and application and kit thereof
WO2020159203A1 (en) * 2019-01-29 2020-08-06 (주)엠디바이오랩 Composition comprising streptonigrin and anticancer agent for preventing or treating brain tumor
JP7485273B2 (en) 2020-06-25 2024-05-16 国立大学法人 鹿児島大学 Method for predicting or determining therapeutic response to cancer with anti-VEGF-A antibody - Patents.com
KR102261368B1 (en) 2020-09-16 2021-06-08 주식회사 라이브러리엔 The sofa of the assembly type

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (en) 1990-01-12 2007-04-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
EP0666868B2 (en) 1992-10-28 2006-06-14 Genentech, Inc. Use of anti-VEGF antibodies for the treatment of cancer
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE211134T1 (en) 1996-03-05 2002-01-15 4-ANILINOQUINAZOLINE DERIVATIVES
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
PL331154A1 (en) 1996-07-13 1999-06-21 Glaxo Group Ltd Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
SI0971959T1 (en) 1997-04-07 2006-06-30 Genentech Inc Humanized antibodies and methods for forming humanized antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE69829891T2 (en) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF antibody
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO1998054093A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
ES2289791T3 (en) 1997-08-22 2008-02-01 Astrazeneca Ab DERIVATIVES OF OXINDOLILQUINAZOLINA AS INHIBITORS OF ANGIOGENESIS.
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2309690A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
CA2312208C (en) 1997-12-05 2011-01-25 The Scripps Research Institute Humanization of murine antibody
JP3591264B2 (en) * 1997-12-24 2004-11-17 富士レビオ株式会社 VEGF121-specific monoclonal antibody and measurement method
DE19806989A1 (en) 1998-02-19 1999-08-26 Roche Diagnostics Gmbh Generation of spatially sharply defined solid phases for binding assays
DK2020408T3 (en) 1998-05-29 2013-09-30 Sugen Inc Pyrrole-substituted 2-indolinone as protein kinase inhibitor
US6387663B1 (en) * 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
CA2359067C (en) 1999-01-15 2017-03-14 Genentech, Inc. Polypeptide variants with altered effector function
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
KR100749982B1 (en) 1999-11-16 2007-08-16 제넨테크, 인크. Elisa for vegf
WO2001077342A1 (en) 2000-04-11 2001-10-18 Genentech, Inc. Multivalent antibodies and uses therefor
US7833525B2 (en) 2000-12-28 2010-11-16 Bhami Shenoy Crystals of whole antibodies and fragments thereof and methods for making and using them
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR20160014775A (en) 2003-05-30 2016-02-11 제넨테크, 인크. Treatment with anti-VEGF antibodies
US20050009110A1 (en) * 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
UA88294C2 (en) * 2004-03-24 2009-10-12 Фейсит Биотек Корпорейшен Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
DE102004029909A1 (en) 2004-06-21 2006-01-19 Roche Diagnostics Gmbh Method and device for the preparation of bindable reagent carriers
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
WO2007145862A2 (en) * 2006-06-05 2007-12-21 Genentech, Inc. Extending survival of cancer patients with elevated levels of egf or tgf-alpha
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
PL2069798T3 (en) 2006-10-04 2014-09-30 Genentech Inc Elisa for vegf
MX2010005057A (en) * 2007-11-09 2010-05-19 Genentech Inc Methods and compositions for diagnostic use in cancer patients.
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
MX350962B (en) 2008-01-07 2017-09-27 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects.
SI2274008T1 (en) * 2008-03-27 2014-08-29 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010075420A1 (en) * 2008-12-23 2010-07-01 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
PE20120591A1 (en) 2009-04-02 2012-05-23 Roche Glycart Ag MULTI-SPECIFIC ANTIBODIES INCLUDING FULL-LENGTH ANTIBODIES AND SINGLE-CHAIN FAB FRAGMENTS
CA2757931C (en) 2009-04-07 2019-03-26 Roche Glycart Ag Trivalent, bispecific antibodies
JP5719354B2 (en) 2009-05-27 2015-05-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Triple or quadrispecific antibody
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
UY32920A (en) 2009-10-02 2011-04-29 Boehringer Ingelheim Int BISPECIFIC UNION MOLECULES FOR ANTI-ANGIOGENESIS THERAPY

Also Published As

Publication number Publication date
RU2013104301A (en) 2014-08-27
US20140023639A1 (en) 2014-01-23
SG187120A1 (en) 2013-02-28
KR20130126588A (en) 2013-11-20
BR112013001433A2 (en) 2016-05-31
US20130243758A1 (en) 2013-09-19
EP2824457A1 (en) 2015-01-14
MX2013000676A (en) 2013-02-27
RU2013104300A (en) 2014-08-27
EP2801826A1 (en) 2014-11-12
US20140056874A1 (en) 2014-02-27
BR112013001429A2 (en) 2016-05-31
SG187119A1 (en) 2013-02-28
CA2805623A1 (en) 2012-01-26
CN104730243A (en) 2015-06-24
WO2012010547A1 (en) 2012-01-26
AU2011281705A1 (en) 2013-01-31
US20130336960A1 (en) 2013-12-19
MX2013000672A (en) 2013-02-27
RU2013104299A (en) 2014-08-27
RU2013104302A (en) 2014-08-27
CN104965084A (en) 2015-10-07
CN104614525A (en) 2015-05-13
WO2012010550A1 (en) 2012-01-26
WO2012010548A1 (en) 2012-01-26
HK1216039A1 (en) 2016-10-07
US20140017231A1 (en) 2014-01-16
CN103270418A (en) 2013-08-28
EP2596358A1 (en) 2013-05-29
US20140056875A1 (en) 2014-02-27
CA2805708A1 (en) 2012-01-26
JP2013534307A (en) 2013-09-02
AU2011281704A1 (en) 2013-01-31
AU2011281705A2 (en) 2013-07-11
CA2805618A1 (en) 2012-01-26
CN104634971A (en) 2015-05-20
EP2848939A1 (en) 2015-03-18
AU2011281702A1 (en) 2013-01-31
CA2805709A1 (en) 2012-01-26
SG10201505414XA (en) 2015-08-28
JP2013534306A (en) 2013-09-02
SG187121A1 (en) 2013-02-28
JP2013534305A (en) 2013-09-02
CN104965084B (en) 2017-09-29
MX2013000674A (en) 2013-04-03
US20130344059A1 (en) 2013-12-26
ZA201300440B (en) 2013-09-25
ZA201300345B (en) 2013-09-25
JP2013537522A (en) 2013-10-03
CN103180736A (en) 2013-06-26
CN103180738A (en) 2013-06-26
US20130336959A1 (en) 2013-12-19
EP2596359A1 (en) 2013-05-29
JP2016014670A (en) 2016-01-28
KR20130055647A (en) 2013-05-28
MX2013000675A (en) 2013-04-03
SG10201505601RA (en) 2015-08-28
JP2016026290A (en) 2016-02-12
US20140193397A1 (en) 2014-07-10
US20140017232A1 (en) 2014-01-16
KR20130126587A (en) 2013-11-20
US20130171135A1 (en) 2013-07-04
BR112013001431A2 (en) 2016-05-31
KR20150013949A (en) 2015-02-05
EP2596361A1 (en) 2013-05-29
US20130183300A1 (en) 2013-07-18
AU2011281701A1 (en) 2013-01-31
ZA201300305B (en) 2013-09-25
KR20130091745A (en) 2013-08-19
EP2596360A1 (en) 2013-05-29
SG10201505593VA (en) 2015-09-29
JP2015180879A (en) 2015-10-15
WO2012010551A1 (en) 2012-01-26
SG187018A1 (en) 2013-02-28
CN103180737A (en) 2013-06-26
JP2015206795A (en) 2015-11-19
EP2866032A1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
HK1216039A1 (en) Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
EP2729214A4 (en) System and methods to facilitate providing therapy to a patient
EP2709694A4 (en) Single-use injector of low cost
EP2726133A4 (en) Improved medical tubing
PT2714922T (en) Method of detecting the resistant microorganisms to a therapeutic agent
GB2501243B (en) Method of making a medical balloon
EP2788752A4 (en) Method of therapy selection for patients with cancer
EP2580658A4 (en) Sessions to host processes with special requirements
EP2739645A4 (en) Treatment of heart failure and related conditions
IL231185B (en) Bio-compatible catheter
EP2652156A4 (en) Method of detecting resistance to cancer therapy
EP2745235A4 (en) Method of drug repositioning
ZA201403739B (en) Methods of treatment with deferiprone
IL218520A0 (en) Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
HRP20181979T1 (en) Medical glue and method of its production
ZA201205997B (en) Treatment of a metabolic disorder
PT2747561T (en) Treatment of symptoms associated with female gastroparesis
EP2688628A4 (en) Delivering diluted oxygen to a patient
EP2773417A4 (en) Implantable medical lead
PL3323835T3 (en) Miniemulsion polymerization to prepare drag reducers
ZA201306597B (en) Sensor for venous networks for a part of a living body
ZA201300344B (en) Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
GB201112632D0 (en) Design implementation of a medical pump
GB201107961D0 (en) Ampole and method of administering a fluid
GB201110540D0 (en) A medical injector